par Schöffski, Patrick;Awada, Ahmad ;Dumez, Herlinde;Gil, Thierry ;Bartholomeus, Sylvie;Wolter, P;Taton, Martine ;Fritsch, Holger;Glomb, Patricia;Munzert, Gerd
Référence European journal of cancer, 48, 2, page (179-186)
Publication Publié, 2012-01
Référence European journal of cancer, 48, 2, page (179-186)
Publication Publié, 2012-01
Article révisé par les pairs
Résumé : | Volasertib (BI 6727) is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinase (Plk). This phase I dose-escalation study evaluated the maximum tolerated dose (MTD) of volasertib, safety and efficacy, and pharmacokinetic (PK) parameters. |